Aceclofenac
Brand names: Preservex
Aceclofenac is an oral non-steroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits cyclo-oxygenase enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation and pain.
Prescribing in practice
- Use the lowest effective dose for the shortest duration because of dose-related gastrointestinal, cardiovascular and renal risks; consider gastroprotection in those at risk.
- Avoid in active gastrointestinal bleeding or ulceration, severe heart failure, and significant renal impairment, and use caution in the elderly.
- The MHRA advises NSAIDs such as aceclofenac are contraindicated in established cardiovascular disease in line with diclofenac restrictions.
Monitoring
Monitor blood pressure, renal function and for gastrointestinal symptoms, particularly in older patients and those on long-term treatment.
Counselling the patient
- Take it with or after food and report any black stools, vomiting blood or severe indigestion.
- Do not combine with other NSAIDs including over-the-counter ibuprofen.
- Seek advice if you develop ankle swelling, breathlessness or reduced urine output.
Evidence & guidelines
MHRA reviews of NSAID cardiovascular safety inform the contraindications and minimum effective dose advice applied to aceclofenac.
Reference: MHRA Drug Safety Update June 2013 (Diclofenac CV risk — class effect); EMA NSAID Safety Review 2013; NICE CKS NSAIDs; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022